{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007179","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.068539+00:00","generated_at":"2026-05-16T22:47:29.976261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias","bullets":["Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.","Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.","Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).","Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.","Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007179","json":"https://secwatch.observer/filing/0001171843-25-007179.json","markdown":"https://secwatch.observer/filing/0001171843-25-007179.md","text":"https://secwatch.observer/filing/0001171843-25-007179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/0001171843-25-007179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/f8k_111025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:47:29.976261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}